公开(公告)号：US20180050097A1

公开(公告)日：2018-02-22

申请号：US15561130

申请日：2016-03-25

Applicant: STC. UNM

Inventor： Kiran Bhaskar ,  Nicole Maphis ,  David S. Peabody ,  Bryce Chackerian ,  Julianne Peabody ,  Erin Crossey

IPC: A61K39/00 ,  A01K67/027 ,  C12N7/00

CPC classification number: A61K39/0007 ,  A01K67/0278 ,  A01K2217/056 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0306 ,  A01K2267/0312 ,  A01K2267/0318 ,  A01K2267/0368 ,  A61K2039/5258 ,  A61K2039/575 ,  C12N7/00 ,  C12N2795/18123 ,  C12N2795/18134 ,  C12N2795/18171

Abstract: This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse.